262 related articles for article (PubMed ID: 2030314)
41. Seropositivity to anti-phenolic glycolipid-I in leprosy cases, contacts and no known contacts of leprosy in an endemic and a non-endemic area in northeast Brazil.
Frota CC; Freitas MV; Foss NT; Lima LN; Rodrigues LC; Barreto ML; Kerr LR
Trans R Soc Trop Med Hyg; 2010 Jul; 104(7):490-5. PubMed ID: 20447668
[TBL] [Abstract][Full Text] [Related]
42. Rapid serodiagnosis for leprosy--a preliminary study on latex agglutination test.
Wu QX; Ye GY; Yin YP; Li XY; Liu Q; Wei WH
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):328-33. PubMed ID: 2198316
[TBL] [Abstract][Full Text] [Related]
43. Serodiagnosis of leprosy: relationships between antibodies to Mycobacterium leprae phenolic glycolipid I and protein antigens.
Levis WR; Meeker HC; Schuller-Levis GB; Gillis TP; Marino LJ; Zabriskie J
J Clin Microbiol; 1986 Dec; 24(6):917-21. PubMed ID: 3537003
[TBL] [Abstract][Full Text] [Related]
44. Anti-PGL-1 antibody levels in Thai leprosy patients.
Kampirapap K; Singtham N
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):728-33. PubMed ID: 9253875
[TBL] [Abstract][Full Text] [Related]
45. Serological evidence of Toxoplasma gondii infection as potential risk for the development of lepromatous leprosy in an endemic area for both neglected tropical diseases in Brazil.
Oliveira LRP; Martins LM; Souza RDC; Scheidegger de Castro Y; Nascimento LS; da Silva JA; Nahn Junior EP; da Silva WD; Peixoto-Rangel AL
Infect Dis Poverty; 2020 Feb; 9(1):19. PubMed ID: 32051036
[TBL] [Abstract][Full Text] [Related]
46. Mycobacterium leprae particle agglutination in diagnosis and monitoring of treatment of leprosy.
Kampirapap K
J Med Assoc Thai; 1999 Oct; 82(10):1020-4. PubMed ID: 10561966
[TBL] [Abstract][Full Text] [Related]
47. The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy.
Spencer JS; Brennan PJ
Lepr Rev; 2011 Dec; 82(4):344-57. PubMed ID: 22439275
[TBL] [Abstract][Full Text] [Related]
48. IgA antibodies against phenolic glycolipid I from Mycobacterium leprae in serum of leprosy patients and contacts: subclass distribution and relation to disease activity.
Schwerer B; Chujor CS; Bernheimer H; Radl J; Haaijman JJ; Meeker HC; Sersen G; Levis WR
Clin Immunol Immunopathol; 1989 Nov; 53(2 Pt 1):202-11. PubMed ID: 2676273
[TBL] [Abstract][Full Text] [Related]
49. Gelatin particle agglutination assay to detect anti-PGL-I antibodies in leprosy patients and in household contacts: a preliminary study.
Mahajan P; Jogaikar DG; Jadhav VH; Mehta JM
Indian J Lepr; 1992; 64(4):461-7. PubMed ID: 1308520
[TBL] [Abstract][Full Text] [Related]
50. Levels of IgG subclasses in active and inactive cases in the disease spectrum of leprosy.
Beuria MK; Parkash O; Joshi B; Mohanty KK; Katoch K; Sengupta U
Int Arch Allergy Immunol; 1998 Jan; 115(1):61-6. PubMed ID: 9430497
[TBL] [Abstract][Full Text] [Related]
51. Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of M. leprae infection in populations of the South Pacific Islands.
Cartel JL; Chanteau S; Boutin JP; Plichart R; Richez P; Roux JF; Grosset JH
Int J Lepr Other Mycobact Dis; 1990 Sep; 58(3):512-7. PubMed ID: 2205686
[TBL] [Abstract][Full Text] [Related]
52. Serological activity of natural disaccharide octyl bovine serum albumin (ND-O-BSA) in sera from patients with leprosy, tuberculosis, and normal controls.
Wu QX; Ye GY; Li XY
Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):50-5. PubMed ID: 3131466
[TBL] [Abstract][Full Text] [Related]
53. A serologic study of naturally acquired leprosy in chimpanzees.
Gormus BJ; Xu KY; Alford PL; Lee DR; Hubbard GB; Eichberg JW; Meyers WM
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):450-7. PubMed ID: 1890369
[TBL] [Abstract][Full Text] [Related]
54. Anti-arabinogalactan IgM/IgG ratio: a screening index for leprosy patients.
Roy A; Agarwal A; Ralhan R
Indian J Lepr; 1990; 62(4):435-42. PubMed ID: 2086678
[TBL] [Abstract][Full Text] [Related]
55. The value of IgM antibodies to PGL-I in the diagnosis of leprosy.
Lefford MJ; Hunegnaw M; Siwik E
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):432-40. PubMed ID: 1890367
[TBL] [Abstract][Full Text] [Related]
56. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
[TBL] [Abstract][Full Text] [Related]
57. Effect of multidrug therapy on the levels of antibodies to Mycobacterium leprae glycolipid-1 in the leprosy spectrum.
Vaishnavi C; Ganguly NK; Sharma VK; Kaur H; Kaur S
Indian J Lepr; 1988 Oct; 60(4):530-4. PubMed ID: 3253332
[TBL] [Abstract][Full Text] [Related]
58. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of antibody responses.
Roche PW; Britton WJ; Failbus SS; Williams D; Pradhan HM; Theuvenet WJ
Int J Lepr Other Mycobact Dis; 1990 Sep; 58(3):480-90. PubMed ID: 2205683
[TBL] [Abstract][Full Text] [Related]
59. The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients.
Britton WJ; Garsia RJ; Basten A
Aust N Z J Med; 1987 Dec; 17(6):568-73. PubMed ID: 3328975
[TBL] [Abstract][Full Text] [Related]
60. Can anti-PGL-1 and anti-NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?
Devides AC; Rosa PS; de Faria Fernandes Belone A; Coelho NMB; Ura S; Silva EA
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):260-265. PubMed ID: 29669693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
